Literature DB >> 20713490

General anaesthesia for external electrical cardioversion of atrial fibrillation: experience of an exclusively cardiological procedural management.

Giovanni Morani1, Corinna Bergamini, Carlo Angheben, Laura Pozzani, Mariantonietta Cicoira, Luca Tomasi, Daniela Lanza, Corrado Vassanelli.   

Abstract

AIMS: External electrical cardioversion (EC) usually requires brief general anaesthesia involving anaesthetists. The aim of this study was to evaluate the feasibility and safety of inducing anaesthesia for EC of atrial fibrillation (AF) exclusively by the cardiologic team with anaesthetists on-hand. METHODS AND
RESULTS: A retrospective analysis of 624 elective EC, over a 6-year period, was made. No patients were excluded due to the severity of pathology or comorbidities. The protocol of the intravenous anaesthesia was 5 mg bolus of midazolam and subsequent increasing doses of propofol starting from 20 mg to achieve the desired sedation level. After delivering DC shock, a direct observation period followed in order to assess the post-sedation recovery and to detect the procedure-related complications. Electrical cardioversion was effective in 98.9% of the cases. General anaesthesia was effective in 100% of cases with a dosage of propofol, ranging between 20 mg to a maximum of 80 mg, after 5 mg of midazolam was administered. All patients generally showed a fast recovery waking up in a few minutes. The anaesthesiology team was never called for assistance. All the procedures were carried out by the cardiologic team as planned. No thrombo-embolic and allergic complications were observed. Arrhythmic complications were uncommon and essentially bradyarrhythmias.
CONCLUSION: A general anaesthesia for outpatient EC of AF can be safely handled by a cardiologist having adequate experience with anaesthetical agents. Moreover, the association of midazolam and a very small dosage of propofol, given their synergic action, is effective and safe in inducing anaesthesia. Arrhythmic complications are rare and limited to bradyarrhythmias.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713490     DOI: 10.1093/europace/euq276

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  6 in total

1.  Effects of propofol sedation on pacing thresholds : Results from an observational cohort study.

Authors:  Jakob Lüker; Arian Sultan; Tobias Plenge; Samuel Lee; Jan-Hendrik van den Bruck; Daniel Steven
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2017-11-14

2.  Ibutilide for the Cardioversion of Paroxysmal Atrial Fibrillation during Radiofrequency Ablation of Supraventricular Tachycardias.

Authors:  Kostas Polymeropoulos; Vassilios P Vassilikos; Lilian Mantziari; Stelios Paraskevaidis; Theodoros D Karamitsos; Sotirios Mochlas; Georgios Parcharidis; Georgios Louridas; Ioannis H Styliadis
Journal:  Cardiol Res Pract       Date:  2011-05-24       Impact factor: 1.866

3.  Inhibition of cardiac Kv1.5 potassium current by the anesthetic midazolam: mode of action.

Authors:  Nadine Vonderlin; Fathima Fischer; Edgar Zitron; Claudia Seyler; Daniel Scherer; Dierk Thomas; Hugo A Katus; Eberhard P Scholz
Journal:  Drug Des Devel Ther       Date:  2014-11-07       Impact factor: 4.162

4.  Cardioversion: What to choose? Etomidate or propofol.

Authors:  Pushkar M Desai; Deepa Kane; Manjula S Sarkar
Journal:  Ann Card Anaesth       Date:  2015 Jul-Sep

Review 5.  Sedation in the Electrophysiology Laboratory: A Multidisciplinary Review.

Authors:  Neal S Gerstein; Andrew Young; Peter M Schulman; Eric C Stecker; Peter M Jessel
Journal:  J Am Heart Assoc       Date:  2016-06-13       Impact factor: 5.501

6.  Procedural sedation for direct current cardioversion: a feasibility study between two management strategies in the emergency department.

Authors:  Giulia Stronati; Alessandro Capucci; Antonio Dello Russo; Erica Adrario; Andrea Carsetti; Michela Casella; Abele Donati; Federico Guerra
Journal:  BMC Cardiovasc Disord       Date:  2020-08-25       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.